Scholars Central

Conference abstractPublished 8 Jun 2018

Same and different: Version 4 of the eCTD standard

Authors: Joel Finkle

ACUTA, LLC, USA

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

The electronic common technical document standard, established in 2003, has been a boon for both regulators and drug sponsors, as it speeds review and provides a consistent framework for market, and investigational trial authorization. It has been implemented in the US, the European Union, Switzerland, South Africa, the Gulf Coast Consortium, and is accepted in many other countries as the primary electronic review medium. Version 4 of the standard is a radical change to the packaging of the authorization dossiersâÂ?Â?but with no change to the actual content. Its benefits include greater flexibility to support more submission and product types, but will require updates to software. With FDA about to accept version 4 in a pilot program, it is critical to learn how this will affect your company. This session will explore the technical issues that will make implementation difficult, but also the similarities that make regulatory’s job nearly unchanged.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Journal of Developing Drugs.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Developing Drugs
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Joel Finkle”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels